Based on prior research, peripheral blood immune cells in NSCLC patients treated with anti-PD-1 therapy undergo varying degrees of change, and different subpopulations may exert distinct functions regardless of treatment efficacy. Here, PDCD1 is linked to non-small cell lung carcinoma.